Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of once-weekly ACP-001 vs daily rhGH in pre-pubertal children with growth hormone deficiency
2012-002787-27Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2012
- Modality
- Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ACP-001 in growth hormone deficiency (GHD) (4 arms), sponsored by Ascendis Pharma. Primary endpoint: Safety and tolerability of ACP-001 vs daily rhGH. Started Dec 2012; status: completed.
02
Drugs
ACP-001
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2012-002787-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002787-27.